| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 159, Issue 11 5509-5515, Copyright © 1997 by American Association of Immunologists
ARTICLES |
U Altenschmidt, E Klundt and B Groner
Institute for Experimental Cancer Research, Tumor Biology Center, Freiburg, Germany.
Adoptive immunotherapy of cancer uses the transfer of tumor-reactive immune cells. The success of this procedure is dependent upon the specificity of the transferred immune cells, their number, and their ability to reach their target cells. We genetically modified T lymphocytes and equipped them with the ability to specifically recognize tumor cells. Tumor cells overexpressing the ErbB-2 receptor served as a model. The target cell recognition specificity is conferred to T lymphocytes by transduction of a chimeric gene encoding the zeta- chain of the TCR and a single chain antibody (scFv(FRP5)) directed against the human ErbB-2 receptor. The chimeric scFv(FRP5)-zeta gene was introduced into primary mouse T lymphocytes via retroviral gene transfer. Naive T lymphocytes were activated and infected by cocultivation with a retrovirus-producing packaging cell line. The scFv(FRP5)-zeta fusion gene was expressed in >75% of the T cells. These T cells lysed ErbB-2-expressing target cells in vitro with high specificity. We tested the antitumor efficacy of scFv(FRP5)-zeta- expressing T cells in a syngeneic BALB/c model. The mice were treated with autologous, transduced T cells. The adoptively transferred scFv(FRP5)-zeta-expressing T cells caused total regression of ErbB-2- expressing tumors. The presence of the transduced T lymphocytes in the tumor tissue was monitored. No humoral response directed against the transduced T cells was observed. Abs directed against the ErbB-2 receptor were detected upon tumor lysis.
This article has been cited by other articles:
|
|
 |
|
  C. M. Kowolik, M. S. Topp, S. Gonzalez, T. Pfeiffer, S. Olivares, N. Gonzalez, D. D. Smith, S. J. Forman, M. C. Jensen, and L. J.N. Cooper CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor Enhances In vivo Persistence and Antitumor Efficacy of Adoptively Transferred T Cells. Cancer Res., November 15, 2006; 66(22): 10995 - 11004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-R. Jiang, D. E. Gilham, K. Mulryan, N. Kirillova, R. E. Hawkins, and P. L. Stern Combination of Vaccination and Chimeric Receptor Expressing T Cells Provides Improved Active Therapy of Tumors J. Immunol., October 1, 2006; 177(7): 4288 - 4298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Kershaw, J. T. Jackson, N. M. Haynes, M. W. L. Teng, M. Moeller, Y. Hayakawa, S. E. Street, R. Cameron, J. E. Tanner, J. A. Trapani, et al. Gene-Engineered T Cells as a Superior Adjuvant Therapy for Metastatic Cancer J. Immunol., August 1, 2004; 173(3): 2143 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Pinthus, T. Waks, K. Kaufman-Francis, D. G. Schindler, A. Harmelin, H. Kanety, J. Ramon, and Z. Eshhar Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes Cancer Res., May 15, 2003; 63(10): 2470 - 2476. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Uherek, T. Tonn, B. Uherek, S. Becker, B. Schnierle, H.-G. Klingemann, and W. Wels Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction Blood, July 30, 2002; 100(4): 1265 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. J. Niederman, Z. Ghogawala, B. S. Carter, H. S. Tompkins, M. M. Russell, and R. C. Mulligan Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors PNAS, May 14, 2002; 99(10): 7009 - 7014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rossig, C. M. Bollard, J. G. Nuchtern, C. M. Rooney, and M. K. Brenner Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy Blood, March 15, 2002; 99(6): 2009 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Haynes, M. B. Snook, J. A. Trapani, L. Cerruti, S. M. Jane, M. J. Smyth, and P. K. Darcy Redirecting Mouse CTL Against Colon Carcinoma: Superior Signaling Efficacy of Single-Chain Variable Domain Chimeras Containing TCR-{{zeta}} vs Fc{{epsilon}}RI-{{gamma}} J. Immunol., January 1, 2001; 166(1): 182 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Darcy, N. M. Haynes, M. B. Snook, J. A. Trapani, L. Cerruti, S. M. Jane, and M. J. Smyth Redirected Perforin-Dependent Lysis of Colon Carcinoma by Ex Vivo Genetically Engineered CTL J. Immunol., April 1, 2000; 164(7): 3705 - 3712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Geiger, D. Leitenberg, and R. A. Flavell The TCR {zeta}-Chain Immunoreceptor Tyrosine-Based Activation Motifs Are Sufficient for the Activation and Differentiation of Primary T Lymphocytes J. Immunol., May 15, 1999; 162(10): 5931 - 5939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Finney, A. D. G. Lawson, C. R. Bebbington, and A. N. C. Weir Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product J. Immunol., September 15, 1998; 161(6): 2791 - 2797. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
